Background: Antidepressant-induced sexual dysfunction affects approximately 50% of patients taking antidepressants. Previous research has explored sildenafil's effectiveness in treating various forms of erectile dysfunction, but there is no research supporting sildenafil's use for improving the quality of life for patients with sexual dysfunction linked to antidepressant use. The authors of this article aimed to assess the improvements in quality of life in patients taking sildenafil to treat antidepressant-induced sexual dysfunction.
Methods: One hundred and two out of 2,239 male and female patients in the follow-up phase of the Sequenced Treatment Alternatives to Relieve Depression antidepressant trials who complained of sexual dysfunction were given sildenafil, 50 to 100 mg, as needed. After 12 months, we measured patients' change in libido, sexual drive, family relationships, overall well-being, satisfaction with treatment, and overall contentment with items on the 17-item Hamilton Depression Rating Scale, Quality of Life Enjoyment and Satisfaction Questionnaire, 30-item Inventory of Depressive Symptoms, and 12-item Short Form Health Survey.
Results: There was a significant association between sildenafil use and improvement in libido and sexual drive by month 6. There was no significant improvement in the quality-of-life scores we examined, but treatment satisfaction and overall contentment increased over time.
Conclusions: Despite no direct association with sildenafil use and quality-of-life scores, sildenafil may be a beneficial treatment for antidepressant-induced sexual dysfunction. A double-blind, placebo-controlled study of sildenafil in antidepressant-induced sexual dysfunction is needed to further explore its potential benefits.
Download full-text PDF |
Source |
---|
Surg Technol Int
January 2025
Department of Psychiatry and Narcology, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation.
Pelvic Venous Disorder (PEVD) and May-Thurner syndrome (MTS) represent relatively understudied vascular issues that can significantly impact patients' quality of life. This study aims to evaluate the efficacy of surgical treatment for PEVD and MTS, conduct a comparative analysis of outcomes, and determine the practical significance of different therapeutic approaches. The study was conducted from 2019 to 2022 in Moscow, Russia, encompassing two outpatient clinics.
View Article and Find Full Text PDFWorld J Urol
January 2025
Urology Department, Faculty of Medicine, Tanta University, Tanta, Egypt.
Purpose: To compare the erectile and urinary functions of ventral and dorsal onlay buccal mucosal graft (BMG) urethroplasty in the management of proximal bulbar urethral strictures (PBUS) in sexually active men.
Patients And Methods: We retrospectively included patients with primary non-traumatic PBUS who were treated with (BMG) urethroplasty at our department between March 2019 and March 2023 either ventral or dorsal approaches. Patients were assessed at 3- and 12-months postoperatively for urinary and erectile functions.
J Sex Marital Ther
January 2025
Clinical Research Department, Elexial Research, Urology, Boston Medical Group, Bogotá, Colombia.
In this study, data from 7,440 patients from six Ibero-American countries were analyzed, focusing on men who consulted for erectile dysfunction (ED). Participants were queried about infidelity in their relationships. Results showed a negative correlation between infidelity and the severity of ED, suggesting that the likelihood of infidelity decreases as the severity of ED increases.
View Article and Find Full Text PDFIndian J Psychiatry
December 2024
Consultant Psychiatrist, Pune, Maharashtra, India.
Background: Psychosexual health is an important aspect of mental and physical wellbeing. Though Indian culture has a rich history of sexuality, over the years, our population has been reticent in talking about the same. With the advent of technology and new legislations protecting the rights of LGBTQIA population, awareness is also on the rise.
View Article and Find Full Text PDFBasic Clin Androl
January 2025
Chair of Endocrinology and Medical Sexology (ENDOSEX), Dept. of Systems Medicine, University of Rome Tor Vergata, via Montpellier 1, Rome, 00133, Italy.
The serendipitous discovery that inhibiting type 5 phosphodiesterase (PDE5) using sildenafil, a potent PDE5 inhibitor (PDE5i) initially developed for cardioprotection, introduced the possibility of orally managing erectile dysfunction (ED) led to an increase in research data, which are currently considered groundbreaking for the new discipline of sexual medicine. Findings from a number of laboratories and clinics around the world unanimously demonstrated the following: (i) the major cause of ED is directly or indirectly related to cardiovascular disease (CVD); (ii) ED and CVDs share the same risk factors, which are related mainly to lifestyle choices; (iii) the first therapeutic approach to both ED and CVDs is to transform harmful lifestyles into virtuous lifestyles; and (iv) PDE5is in general, particularly sildenafil, are very safe, if not protective, for use in CVD patients. However, the use of PDE5is has faced several challenges.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!